PriceTargets.com logo

PTC Therapeutics - PTCT Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $54.08
  • Forecasted Upside: 16.95%
  • Number of Analysts: 15
  • Breakdown:
  • 3 Sell Ratings
  • 3 Hold Ratings
  • 8 Buy Ratings
  • 1 Strong Buy Ratings
$46.24 As of 12/20/2024 06:16 PM ET
▲ +0.99 (2.19%)

This chart shows the closing price for PTCT by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New PTC Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for PTCT and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for PTCT

Analyst Price Target is $54.08
▲ +16.95% Upside Potential
This price target is based on 15 analysts offering 12 month price targets for PTC Therapeutics in the last 3 months. The average price target is $54.08, with a high forecast of $71.00 and a low forecast of $30.00. The average price target represents a 16.95% upside from the last price of $46.24.

This chart shows the closing price for PTCT for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Hold

The current consensus among 15 investment analysts is to hold stock in PTC Therapeutics. This rating has held steady since April 2024, when it changed from a Reduce consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 5 buy ratings
  • 5 hold ratings
  • 1 sell ratings
Ratings as of
6/29/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 7 hold ratings
  • 3 sell ratings
Ratings as of
9/27/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 6 hold ratings
  • 5 sell ratings
Ratings as of
12/26/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 5 hold ratings
  • 5 sell ratings
Ratings as of
3/25/2024
  • 0 strong buy ratings
  • 4 buy ratings
  • 7 hold ratings
  • 3 sell ratings
Ratings as of
6/23/2024
  • 1 strong buy ratings
  • 6 buy ratings
  • 6 hold ratings
  • 3 sell ratings
Ratings as of
9/21/2024
  • 1 strong buy ratings
  • 6 buy ratings
  • 5 hold ratings
  • 3 sell ratings
Ratings as of
11/20/2024
  • 1 strong buy ratings
  • 8 buy ratings
  • 3 hold ratings
  • 3 sell ratings
Ratings as of
12/20/2024

Latest Recommendations

  • 1 strong buy ratings
  • 8 buy ratings
  • 3 hold ratings
  • 3 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
12/13/2024Morgan StanleyUpgradeEqual Weight ➝ Overweight$45.00 ➝ $67.00
12/4/2024CitigroupBoost TargetSell ➝ Sell$26.00 ➝ $32.00
12/4/2024The Goldman Sachs GroupBoost TargetSell ➝ Sell$32.00 ➝ $42.00
12/3/2024UBS GroupBoost TargetBuy ➝ Buy$47.00 ➝ $71.00
12/3/2024BarclaysBoost TargetEqual Weight ➝ Equal Weight$45.00 ➝ $56.00
12/3/2024Robert W. BairdBoost TargetOutperform ➝ Outperform$52.00 ➝ $70.00
12/3/2024Royal Bank of CanadaUpgradeSector Perform ➝ Outperform$39.00 ➝ $63.00
11/27/2024Robert W. BairdBoost TargetOutperform ➝ Outperform$48.00 ➝ $52.00
11/26/2024Wells Fargo & CompanyBoost TargetOverweight ➝ Overweight$56.00 ➝ $68.00
11/19/2024JPMorgan Chase & Co.Boost TargetOverweight ➝ Overweight$51.00 ➝ $62.00
11/11/2024BarclaysBoost TargetEqual Weight ➝ Equal Weight$31.00 ➝ $43.00
11/8/2024Robert W. BairdBoost TargetOutperform ➝ Outperform$44.00 ➝ $48.00
10/11/2024Morgan StanleyBoost TargetEqual Weight ➝ Equal Weight$32.00 ➝ $45.00
10/10/2024Raymond JamesInitiated CoverageMarket Perform
10/8/2024Robert W. BairdReiterated RatingOutperform ➝ Outperform$44.00 ➝ $44.00
10/4/2024Royal Bank of CanadaBoost TargetSector Perform ➝ Sector Perform$32.00 ➝ $34.00
9/17/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$64.00 ➝ $64.00
9/4/2024Baird R WUpgradeStrong-Buy
9/4/2024Robert W. BairdInitiated CoverageOutperform$44.00
8/26/2024UBS GroupInitiated CoverageNeutral ➝ Buy$47.00
8/21/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$64.00 ➝ $64.00
8/9/2024Cantor FitzgeraldBoost TargetOverweight ➝ Overweight$62.00 ➝ $64.00
8/9/2024BarclaysBoost TargetEqual Weight ➝ Equal Weight$25.00 ➝ $31.00
7/16/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$62.00 ➝ $62.00
7/12/2024Morgan StanleyBoost TargetEqual Weight ➝ Equal Weight$30.00 ➝ $32.00
7/1/2024Cantor FitzgeraldBoost TargetOverweight ➝ Overweight$52.00 ➝ $62.00
6/21/2024Bank of AmericaBoost TargetUnderperform ➝ Underperform$25.00 ➝ $32.00
6/20/2024JPMorgan Chase & Co.Reiterated RatingOverweight ➝ Overweight$53.00 ➝ $53.00
5/28/2024The Goldman Sachs GroupBoost TargetSell ➝ Sell$18.00 ➝ $32.00
5/21/2024CitigroupBoost TargetSell ➝ Sell$18.00 ➝ $26.00
5/21/2024JPMorgan Chase & Co.Boost TargetOverweight ➝ Overweight$43.00 ➝ $53.00
5/21/2024The Goldman Sachs GroupBoost TargetSell ➝ Sell$18.00 ➝ $32.00
5/20/2024Jefferies Financial GroupBoost TargetBuy ➝ Buy$35.00 ➝ $46.00
5/20/2024Raymond JamesUpgradeUnderperform ➝ Market Perform
4/29/2024Morgan StanleyUpgradeUnderweight ➝ Equal Weight$28.00 ➝ $30.00
4/12/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$45.00
3/20/2024Jefferies Financial GroupBoost TargetBuy ➝ Buy$33.00 ➝ $35.00
3/1/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$45.00
3/1/2024Royal Bank of CanadaBoost TargetSector Perform ➝ Sector Perform$22.00 ➝ $28.00
3/1/2024TD CowenLower TargetMarket Perform ➝ Market Perform$32.00 ➝ $30.00
1/26/2024Cantor FitzgeraldLower TargetOverweight ➝ Overweight$51.00 ➝ $45.00
1/26/2024Royal Bank of CanadaLower TargetSector Perform ➝ Sector Perform$27.00 ➝ $22.00
12/19/2023Morgan StanleyDowngradeEqual Weight ➝ Underweight$28.00
12/18/2023Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$51.00
12/8/2023Wells Fargo & CompanyInitiated CoverageOverweight$37.00
11/20/2023Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$51.00
10/27/2023Morgan StanleyLower TargetEqual Weight ➝ Equal Weight$31.00 ➝ $28.00
10/27/2023BarclaysLower TargetEqual Weight ➝ Equal Weight$26.00 ➝ $25.00
10/27/2023CitigroupDowngradeNeutral ➝ Sell$29.00 ➝ $17.00
10/5/2023Truist FinancialDowngradeBuy ➝ Hold$45.00 ➝ $25.00
9/19/2023Bank of AmericaLower TargetUnderperform ➝ Underperform$43.00 ➝ $23.00
9/18/2023Truist FinancialLower TargetBuy ➝ Buy$60.00 ➝ $45.00
9/18/2023Leerink PartnersLower Target$44.00 ➝ $30.00
9/18/2023Morgan StanleyLower TargetEqual Weight ➝ Equal Weight$47.00 ➝ $31.00
9/18/2023The Goldman Sachs GroupLower TargetSell ➝ Sell$35.00 ➝ $22.00
9/18/2023Royal Bank of CanadaLower TargetSector Perform ➝ Sector Perform$49.00 ➝ $26.00
9/18/2023JPMorgan Chase & Co.Lower Target$70.00 ➝ $53.00
9/18/2023BarclaysLower TargetEqual Weight ➝ Equal Weight$44.00 ➝ $26.00
9/18/2023CitigroupDowngradeBuy ➝ Neutral$55.00 ➝ $28.00
9/15/2023Raymond JamesDowngradeOutperform ➝ Underperform
8/16/2023Truist FinancialReiterated RatingBuy ➝ Buy$65.00
8/7/2023Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$73.00
8/4/2023Morgan StanleyReiterated RatingEqual Weight ➝ Equal Weight$47.00
8/4/2023BarclaysLower TargetEqual Weight ➝ Equal Weight$48.00 ➝ $44.00
8/4/2023Raymond JamesLower TargetOutperform ➝ Outperform$58.00 ➝ $55.00
7/20/2023Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$73.00
7/20/2023Royal Bank of CanadaReiterated RatingSector Perform ➝ Sector Perform$49.00
7/20/2023Credit Suisse GroupReiterated RatingNeutral ➝ Neutral$50.00
6/30/2023Cantor FitzgeraldLower TargetOverweight$75.00 ➝ $73.00
5/24/2023Credit Suisse GroupLower Target$55.00 ➝ $50.00
5/24/2023CitigroupLower Target$70.00 ➝ $63.00
5/24/2023BarclaysLower Target$57.00 ➝ $48.00
5/18/2023VNET GroupReiterated RatingMaintains
5/18/2023Bank of AmericaBoost Target$36.00 ➝ $43.00
5/18/2023CitigroupBoost Target$67.00 ➝ $70.00
5/18/2023BarclaysBoost Target$47.00 ➝ $57.00
5/17/2023The Goldman Sachs GroupBoost Target$35.00 ➝ $37.00
5/8/2023JPMorgan Chase & Co.Boost Target$57.00 ➝ $64.00
4/28/2023Credit Suisse GroupBoost Target$48.00 ➝ $51.00
4/28/2023CitigroupBoost Target$61.00 ➝ $67.00
4/18/2023Truist FinancialBoost Target$60.00 ➝ $65.00
3/22/2023William BlairReiterated RatingOutperform
3/17/2023Leerink PartnersReiterated RatingMarket Perform$48.00
3/17/2023SVB SecuritiesInitiated CoverageMarket Perform$48.00
2/23/2023Raymond JamesLower TargetOutperform$60.00 ➝ $55.00
2/22/2023Royal Bank of CanadaBoost Target$44.00 ➝ $51.00
2/22/2023Cantor FitzgeraldLower TargetOverweight$68.00 ➝ $66.00
2/22/2023Credit Suisse GroupReiterated RatingNeutral$48.00
2/3/2023Morgan StanleyBoost TargetEqual Weight$40.00 ➝ $50.00
1/10/2023Credit Suisse GroupBoost TargetNeutral$47.00 ➝ $48.00
12/14/2022The Goldman Sachs GroupInitiated CoverageSell$35.00
11/1/2022CowenLower Target$44.00
11/1/2022BarclaysLower Target$47.00
10/28/2022Royal Bank of CanadaLower TargetSector Perform$60.00 ➝ $46.00
10/28/2022Morgan StanleyLower TargetEqual Weight$54.00 ➝ $40.00
10/28/2022Credit Suisse GroupLower TargetNeutral$55.00 ➝ $47.00
10/17/2022Royal Bank of CanadaBoost TargetSector Perform$49.00 ➝ $60.00
9/12/2022Jefferies Financial GroupInitiated CoverageBuy$62.00
9/9/2022Morgan StanleyInitiated CoverageEqual Weight$54.00
9/1/2022CitigroupInitiated CoverageBuy$70.00
8/11/2022Raymond JamesBoost TargetOutperform$55.00 ➝ $60.00
8/9/2022Credit Suisse GroupBoost Target$55.00
7/22/2022Credit Suisse GroupBoost Target$52.00
6/23/2022Royal Bank of CanadaBoost TargetSector Perform$42.00 ➝ $46.00
4/1/2022Cantor FitzgeraldReiterated RatingOverweight$64.00 ➝ $63.00
2/23/2022JPMorgan Chase & Co.Boost TargetOverweight$70.00 ➝ $76.00
2/23/2022BarclaysLower TargetEqual Weight$40.00 ➝ $39.00
10/29/2021Raymond JamesLower TargetOutperform$70.00 ➝ $55.00
10/29/2021Royal Bank of CanadaLower TargetSector Perform$45.00 ➝ $42.00
10/29/2021Credit Suisse GroupLower TargetNeutral$50.00 ➝ $48.00
10/18/2021Bank of AmericaDowngradeNeutral ➝ Underperform$38.00
8/31/2021UBS GroupLower TargetNeutral$55.00 ➝ $45.00
7/30/2021Credit Suisse GroupLower TargetNeutral$54.00 ➝ $50.00
6/3/2021William BlairReiterated RatingBuy
5/17/2021Truist FinancialLower TargetBuy$75.00 ➝ $65.00
4/26/2021Credit Suisse GroupInitiated CoverageNeutral$54.00
3/29/2021Royal Bank of CanadaUpgradeUnderperform ➝ Sector Perform$47.00
2/26/2021Cantor FitzgeraldLower TargetOverweight$81.00 ➝ $75.00
2/12/2021Bank of AmericaDowngradeBuy ➝ Neutral
1/5/2021Smith Barney CitigroupUpgradeNeutral ➝ Buy
12/16/2020Raymond JamesBoost TargetOutperform$63.00 ➝ $70.00
11/30/2020Royal Bank of CanadaDowngradeSector Perform ➝ Underperform$45.00
10/30/2020Smith Barney CitigroupDowngradeBuy ➝ Neutral
10/30/2020Cantor FitzgeraldLower TargetOverweight$75.00 ➝ $67.00
10/28/2020UBS GroupInitiated CoverageNeutral$55.00
10/7/2020JPMorgan Chase & Co.UpgradeNeutral ➝ Overweight$71.00
9/23/2020Raymond JamesReiterated RatingBuy
8/24/2020Raymond JamesInitiated CoverageOutperform$63.00
8/11/2020Cantor FitzgeraldLower TargetOverweight$85.00 ➝ $75.00
8/10/2020Bank of AmericaLower TargetBuy$60.00 ➝ $58.00
8/10/2020Credit Suisse GroupLower TargetNeutral$53.00 ➝ $52.00
7/20/2020CowenReiterated RatingHold$50.00
7/20/2020Credit Suisse GroupDowngradeOutperform ➝ Neutral$53.00
7/20/2020SunTrust BanksBoost TargetBuy$75.00 ➝ $86.00
5/1/2020SunTrust BanksLower TargetBuy$78.00 ➝ $75.00
4/28/2020William BlairReiterated RatingBuy
4/9/2020CitigroupUpgradeNeutral ➝ Buy$71.00 ➝ $67.00
4/8/2020Cantor FitzgeraldLower TargetOverweight$86.00 ➝ $85.00
4/8/2020Royal Bank of CanadaReiterated RatingHold$45.00
3/4/2020BarclaysReiterated RatingHold$51.00
3/3/2020Cantor FitzgeraldReiterated RatingPositive ➝ Overweight$81.00 ➝ $86.00
3/2/2020CowenReiterated RatingHold
2/20/2020CitigroupDowngradeBuy ➝ Neutral$55.00 ➝ $71.00
2/20/2020Royal Bank of CanadaDowngradeOutperform ➝ Sector Perform$63.00 ➝ $60.00
2/6/2020SunTrust BanksReiterated RatingBuy$78.00
2/6/2020CowenReiterated RatingHold
1/23/2020Cantor FitzgeraldBoost TargetOverweight$60.00 ➝ $81.00
1/15/2020Cantor FitzgeraldReiterated RatingBuy$60.00
(Data available from 12/21/2019 forward)

News Sentiment Rating

0.67 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 9 very positive mentions
  • 22 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
5/25/2024
  • 9 very positive mentions
  • 8 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
6/24/2024
  • 12 very positive mentions
  • 11 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/24/2024
  • 11 very positive mentions
  • 10 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
8/23/2024
  • 6 very positive mentions
  • 11 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/22/2024
  • 15 very positive mentions
  • 18 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
Mentions as of
10/22/2024
  • 7 very positive mentions
  • 26 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
11/21/2024
  • 24 very positive mentions
  • 31 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
Mentions as of
12/21/2024

Current Sentiment

  • 24 very positive mentions
  • 31 positive mentions
  • 3 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

Negative

Positive

Very Positive

PTC Therapeutics logo
PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and ferroptosis and inflammation platforms, including vatiquinone to treat Friedreich ataxia and utreloxastat for the treatment of amyotrophic lateral sclerosis. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd, Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.
Read More

Today's Range

Now: $46.24
Low: $44.74
High: $47.42

50 Day Range

MA: $43.50
Low: $36.70
High: $52.07

52 Week Range

Now: $46.24
Low: $23.58
High: $54.16

Volume

1,431,601 shs

Average Volume

849,432 shs

Market Capitalization

$3.57 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.63

Frequently Asked Questions

What sell-side analysts currently cover shares of PTC Therapeutics?

The following sell-side analysts have issued research reports on PTC Therapeutics in the last twelve months: Baird R W, Bank of America Co., Barclays PLC, Cantor Fitzgerald, Citigroup Inc., Jefferies Financial Group Inc., JPMorgan Chase & Co., Morgan Stanley, Raymond James, Robert W. Baird, Royal Bank of Canada, StockNews.com, TD Cowen, The Goldman Sachs Group, Inc., UBS Group AG, and Wells Fargo & Company.
View the latest analyst ratings for PTCT.

What is the current price target for PTC Therapeutics?

0 Wall Street analysts have set twelve-month price targets for PTC Therapeutics in the last year. Their average twelve-month price target is $54.08, suggesting a possible upside of 16.9%. UBS Group AG has the highest price target set, predicting PTCT will reach $71.00 in the next twelve months. TD Cowen has the lowest price target set, forecasting a price of $30.00 for PTC Therapeutics in the next year.
View the latest price targets for PTCT.

What is the current consensus analyst rating for PTC Therapeutics?

PTC Therapeutics currently has 3 sell ratings, 3 hold ratings, 8 buy ratings and 1 strong buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in PTCT, but not buy more shares or sell existing shares.
View the latest ratings for PTCT.

What other companies compete with PTC Therapeutics?

Other companies that are similar to PTC Therapeutics include Summit Therapeutics, Genmab A/S, Dr. Reddy's Laboratories, Sarepta Therapeutics and Catalent. Learn More about companies similar to PTC Therapeutics.

How do I contact PTC Therapeutics' investor relations team?

PTC Therapeutics' physical mailing address is 100 CORPORATE COURT, SOUTH PLAINFIELD NJ, 07080. The biopharmaceutical company's listed phone number is (908) 222-7000 and its investor relations email address is [email protected]. The official website for PTC Therapeutics is www.ptcbio.com. Learn More about contacing PTC Therapeutics investor relations.